Swerdlow S H
Division of Hematopathology, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Mod Pathol. 1999 Feb;12(2):125-40.
As defined in the proposed World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues, the small B-cell lymphomas include B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, nodal marginal zone lymphoma, lymphoplasmacytic lymphoma, and splenic marginal zone B-cell lymphoma. These neoplasms are recognized mostly on the basis of their histopathologic features, but ancillary studies are useful in confirming and sometimes making the diagnosis. Clinically, the small B-cell lymphomas of lymph nodes and spleen (but not those of MALT type) are usually disseminated at diagnosis and considered incurable. With the exception of mantle cell lymphoma, however, they are generally indolent. The small B-cell lymphomas are among the best examples of how malignant lymphomas can be related to the normal immune system. Although uncertainties exist, these lymphomas are generally considered the neoplastic equivalents of normal B-cell compartments. From a molecular perspective, mantle cell and follicular lymphomas are the best characterized. In both cases, there are characteristic chromosomal translocations involving the immunoglobulin heavy chain and the cyclin D1 or bcl-2 genes, respectively, that are probably followed by additional molecular events leading to overt neoplasia. Variable proportions of the small B-cell lymphomas undergo transformation that might be associated with abnormalities in tumor suppressor genes / cell cycle regulatory proteins. After a brief review of normal B-cell development, the major small B-cell lymphomas (except for those of MALT type) will be discussed in terms of their morphologic features, immunophenotype (including paraffin-section immunostaining), genotype, karyotype, and clinical features, including disease evolution.
按照世界卫生组织提议的造血和淋巴组织肿瘤性疾病分类的定义,小B细胞淋巴瘤包括B细胞慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、套细胞淋巴瘤、滤泡性淋巴瘤、黏膜相关淋巴组织(MALT)型边缘区B细胞淋巴瘤、结内边缘区淋巴瘤、淋巴浆细胞淋巴瘤和脾边缘区B细胞淋巴瘤。这些肿瘤大多根据其组织病理学特征来识别,但辅助检查有助于确诊,有时甚至有助于做出诊断。临床上,淋巴结和脾脏的小B细胞淋巴瘤(但MALT型除外)在诊断时通常已播散,被认为无法治愈。然而,除套细胞淋巴瘤外,它们一般进展缓慢。小B细胞淋巴瘤是恶性淋巴瘤与正常免疫系统相关的最佳例证之一。尽管仍存在不确定性,但这些淋巴瘤通常被认为是正常B细胞区室的肿瘤对应物。从分子角度来看,套细胞淋巴瘤和滤泡性淋巴瘤的特征最为明确。在这两种情况下,分别存在涉及免疫球蛋白重链和细胞周期蛋白D1或bcl-2基因的特征性染色体易位,随后可能会发生其他分子事件,导致明显的肿瘤形成。不同比例的小B细胞淋巴瘤会发生转化,这可能与肿瘤抑制基因/细胞周期调节蛋白的异常有关。在简要回顾正常B细胞发育之后,将讨论主要的小B细胞淋巴瘤(MALT型除外)的形态学特征、免疫表型(包括石蜡切片免疫染色)、基因型、核型以及临床特征,包括疾病进展情况。